211. Fundamental investigation of BIOMIRA CA-125 RIA kit
نویسندگان
چکیده
منابع مشابه
Analytical and Clinical Performance of Improved Abbott lMx CA 125 Assay: Comparison with Abbott CA 125 RIA
We compared the improved Abbott lMx cancer antigen (CA) 125 assay (cat. no. 7A89) with the Abbott CA 125 RIA. Serum specimens were from healthy perimenopausal women (n = 124) and from patients with benign gynecologic and nongynecologic diseases (n = 124), ovarian carcinoma (n = 104), or other malignancies (n = 193). The lMx assay detected as little as 0.193 kAU/L CA 125 (AU = arbitrary Abbott u...
متن کاملAnalytical and clinical performance of improved Abbott IMx CA 125 assay: comparison with Abbott CA 125 RIA.
We compared the improved Abbott IMx cancer antigen (CA) 125 assay (cat. no. 7A89) with the Abbott CA 125 RIA. Serum specimens were from healthy perimenopausal women (n = 124) and from patients with benign gynecologic and nongynecologic diseases (n = 124), ovarian carcinoma (n = 104), or other malignancies (n = 193). The IMx assay detected as little as 0.193 kAU/L CA 125 (AU = arbitrary Abbott u...
متن کاملGuidelines for CA-125 Requesting
The best available marker for epithelial ovarian cancer is still considered to be CA-125 due to a combination of reliability and general availability. HE4 is more sensitive than specific than CA-125, however the former is not in routine use. NICE still therefore recommends CA-125 rather than HE4. CA-125 is used for the diagnosis of epithelial ovarian cancer. αFP and βHCG are useful for identify...
متن کاملSerum CA 125 and ovarian cancer
of death from gynaecological cancer among women in Western countries. Epithelial ovarian cancer is responsible for 85-90% of all primary ovarian tumours. Because of the asymptomatic nature of the disease, ovarian cancer is usually not detected in the early stages and therefore many women present with advanced disease and systemic metastases. Approximately 70-80% of patients present with late st...
متن کاملHE4, CA-125, and cystic ovarian mass
To the editor: The recent publication on ‘HE4, CA-125, and cystic ovarian mass’ is very interesting [1]. Partheen et al. [1] concluded that HE4 did not outperform CA-125. Indeed, the use of two biomarkers might be expected for increased screening ability; however, the problem of the cost should be kept in mind. Incremental analysis on additional cost should be done. Based on the present report,...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Radiological Technology
سال: 1991
ISSN: 0369-4305,1881-4883
DOI: 10.6009/jjrt.kj00003323953